(IMTX) |
| 0 (0%) 10-10 14:19 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 12.79 |
| Resistance 1: | 10.95 |
| Pivot price: | 8.69 |
| Support 1: | 7.69 |
| Support 2: | 5.67 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -78300000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -61.230 |
| Profit Margin (%) | -57.45 |
| Operating Margin (%) | -1.00 |
| Return on Assets (ttm) | 121.5 |
| Return on Equity (ttm) | -9.1 |
Company news
Fri, 10 Oct 2025
Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 (NASDAQ:IMTX) - Seeking Alpha
Thu, 09 Oct 2025
Immatics' (IMTX) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Fri, 03 Oct 2025
Will Immatics (IMTX) Gain Momentum as New CFO Brings Biopharma Commercialization Expertise? - simplywall.st
Fri, 03 Oct 2025
Will Immatics (IMTX) Gain Momentum as New CFO Brings Biopharma Commercialization Expertise? - Sahm
Thu, 02 Oct 2025
Immatics Appoints New CFO to Drive PRAME Therapy Commercialization - The Globe and Mail
Wed, 01 Oct 2025
Immatics (IMTX) Appoints New CFO to Drive Strategic Initiatives - GuruFocus
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
